Sirnaomics Yönetim

Yönetim kriter kontrolleri 0/4

Sirnaomics CEO'su Hung Fai Poon, Nov2024 tarihinde atandı, in görev süresi bir yıldan az. şirketin hisselerinin 20.19% doğrudan sahiptir ve bu hisselerin değeri HK$ 49.08M dir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 0 yıl ve 2.9 yıldır.

Anahtar bilgiler

Hung Fai Poon

İcra Kurulu Başkanı

n/a

Toplam tazminat

CEO maaş yüzdesi	n/a
CEO görev süresi	no data
CEO sahipliği	20.2%
Yönetim ortalama görev süresi	Veri yok
Yönetim Kurulu ortalama görev süresi	2.9yrs

Son yönetim güncellemeleri

Recent updates

CEO

Hung Fai Poon (46 yo)

no data

Görev süresi

Dr. Hung Fai Poon is the Chief Executive Officer of Sirnaomics Ltd. since November 5, 2024 and serves as its Executive Director since October 15, 2024. Dr. Poon has years of experience in the biotechnology...

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Yang Lu	Founder	4.1yrs	US$1.09m	10.7% HK$ 26.0m
Hung Fai Poon	Chief Executive Officer & Executive Director	less than a year	Veri yok	20.19% HK$ 49.1m
Monin Ung	Independent Non Executive Director	2.9yrs	US$69.00k	Veri yok
Cheung-Hoi Yu	Independent Non Executive Director	2.9yrs	US$46.00k	Veri yok
Frederick C. Beddingfield	Chairman of Sagesse Bio Inc.	less than a year	Veri yok	Veri yok
Mo Han Shing	Independent Non-Executive Director	2.9yrs	US$69.00k	Veri yok
Jiankang Zhang	Non Executive Director	3.3yrs	US$15.00k	Veri yok
Mincong Huang	Non Executive Director	3.8yrs	US$15.00k	1.1% HK$ 2.7m

2.9yrs

Ortalama Görev Süresi

63yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: 2257 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilmiyor ( 2.9 yıllık ortalama görev süresi), bu da yeni bir yönetim kurulu olduğunu gösteriyor.

Sirnaomics Yönetim

Yönetim kriter kontrolleri 0/4

Anahtar bilgiler

Son yönetim güncellemeleri

Sirnaomics Ltd. Announces Board and Committee Changes

Sirnaomics Ltd. Appoints Poon Hung Fai as Executive Director

Gore Range Capital LLC and Sirnaomics Ltd. Announces Management of the New Venture Sagesse Bio, Inc

Sirnaomics Ltd. Announces Resignation of Dr. Xiaochang Dai as Chief Strategy Officer

Sirnaomics Ltd. Appoints Edward Yongxiang Wang as Executive Director

Sirnaomics Ltd., Annual General Meeting, Jun 20, 2024

Recent updates

Sirnaomics Ltd. Announces Board and Committee Changes

Sirnaomics Ltd. Appoints Poon Hung Fai as Executive Director

Sirnaomics Ltd. to Report First Half, 2024 Results on Aug 30, 2024

Gore Range Capital LLC and Sirnaomics Ltd. Announces Management of the New Venture Sagesse Bio, Inc

Sirnaomics Ltd. Announces Completion of IND-Enabling Studies of Safety and Efficacy for STP125G with NHP Models, Targeting ApoC3 for Treatment of Cardiovascular Diseases

Sirnaomics Announces Completion Of STP707 Phase I Clinical Study Withstrong Safety Profile and Stable Disease Activityfor the Treatment of Pancreatic Cancer Patients

Sirnaomics Ltd. Announces Resignation of Dr. Xiaochang Dai as Chief Strategy Officer

Sirnaomics Ltd. Appoints Edward Yongxiang Wang as Executive Director

Sirnaomics Ltd., Annual General Meeting, Jun 20, 2024

Board Member recently sold HK$14m worth of stock

New minor risk - Financial data availability

Sirnaomics Ltd. to Report Fiscal Year 2023 Results on Mar 27, 2024

Board Member recently sold HK$8.1m worth of stock

Now 29% undervalued after recent price drop

New major risk - Revenue and earnings growth

Sirnaomics Ltd. Announces Successful Completion of Cohort 1 from Phase I Clinical Study of GalNAc-Based RNAi Therapeutic STP122G for Anticoagulant Treatment

China Chief Scientific Officer recently bought HK$2.8m worth of stock

Sirnaomics Ltd. Announces Executive Changes

Sirnaomics Ltd. Presents Positive Clinical Data of STP705 for Focal Fat Reduction

Sirnaomics Ltd. Announces Appointment of Chief Strategy Officer and Resignation of Joint Company Secretary

Sirnaomics Ltd. Announces Successful Phase I Clinical Study of RNAi Therapeutic STP707 for Treatment of Multiple Solid Tumors

Sirnaomics Ltd. to Report Q2, 2023 Results on Aug 30, 2023

Sirnaomics Ltd. Appoints Francois Lebel as Senior Vice President for Preclinical and Clinical Development

Sirnaomics Ltd. Establishes Strategic Partnership with Edirna Inc

Sirnaomics Advances STP705 for Squamous Cellcarcinoma in Situ into Late-Stage Clinical development

Sirnaomics Ltd. Reports Interim Results of STP705 Phase I Clinical Study for Medical Aesthetics Treatment in Adults Undergoing Abdominoplasty

Sirnaomics Ltd. Doses the First Participant in Phase I Clinical Study of Galnac-Based Rnai Therapeutic STP122G for Anticoagulant Treatment

Sirnaomics Ltd. to Receive Subsidy for Subsidy HKSTP Clinical Translational Catalyst Plan

China Chief Scientific Officer recently sold HK$3.0m worth of stock

Board Member exercised options and sold HK$2.2m worth of stock

Sirnaomics Ltd. Accelerates Clinical Development of STP705 for the Treatment of Non-Melanoma Skin Cancers

China Chief Scientific Officer exercised options to buy HK$22m worth of stock.

China Chief Scientific Officer recently sold HK$702k worth of stock

Sirnaomics Ltd. Announces Interim Data from Phase I Clinical Trial of RNAi Therapeutic STP707 for Treatment of Multiple Solid Tumors

Sirnaomics Ltd. Announces Positive Interim Datafrom Phase IIB Clinical Trial of Stp705 in Adultswith Cutaneous Squamous Cell Carcinoma in Situ

Sirnaomics Ltd. Announces CFO Changes

Less than half of directors are independent

Sirnaomics Ltd. Announces Estimated Commercialization Timeline of STP705

Sirnaomics Ltd. Doses First Patient in Phase I Clinical Trial of RNAi Therapeutic STP705 in Adults Undergoing Abdominoplasty for Medical Aesthetics Treatment

China Chief Scientific Officer recently sold HK$1.7m worth of stock

Sirnaomics to Present Latest Developments on Sirna Therapeutics for Cancer and Galaheadtm Platform Programs At the 2Nd Annual Oligonucleotide Therapeutics and Delivery Conference

China Chief Scientific Officer exercised options to buy HK$14m worth of stock.

Sirnaomics Achieves 100% Complete Response in Phase II Clinical Trial of STP705 for Treatment of Cutaneous Basal Cell Carcinoma

Sirnaomics Ltd. Advances Galahead-Based RNAi Therapeutics for Treatment of Complement-Related Diseases

Sirnaomics Ltd. Announces Resignation of Mr. Da Liu as Non-Executive Director with Effect from September 30, 2022

Sirnaomics Ltd. Doses the First Patient in Phase I/II Clinical Study of RNAi Therapeutic STP705 for Treatment of Facial Squamous Cell Skin Cancer in SITU

Sirnaomics Ltd. to Report First Half, 2022 Results on Aug 30, 2022

Sirnaomics Develops Peptide Docking Vehicle (PDoV(TM)) Designed for an Enhanced GalNAc Delivery Platform for Novel siRNA Therapeutics

Sirnaomics Ltd. Receives IND Clearance from the Taiwan Ministry of Health and Welfare for Phase I Clinical Study of RNAi Therapeutic STP705 for Liver Cancer Treatment

Sirnaomics Ltd. Announces Board Changes

Sirnaomics Ltd. Announces Publication of STP705 Clinical Study Results for Treatment of is SCC in the Peer-Reviewed Journal of Drugs in Dermatology

Sirnaomics Ltd. Launches Phase I Clinical Trial of RNAi Therapeutic STP705 in Adults Undergoing Abdominoplasty for Medical Cosmetology Treatment

Non Executive Director recently sold HK$2.1m worth of stock

Sirnaomics Ltd. Presents Clinical Study Results and Development Strategy for Cancer RNA Therapeutics At the 2022 Pre-Asco China Summit

Less than half of directors are independent

Sirnaomics Ltd. Doses First Subject in Phase I Clinical Trial of STP707 for the Treatment of Liver Fibrosis in Primary Sclerosing Cholangitis

Sirnaomics Ltd., Annual General Meeting, Jun 28, 2022

Sirnaomics Ltd. to Report Fiscal Year 2021 Results on Mar 31, 2022

Sirnaomics Ltd. Announces Interim Data from Phase II Clinical Trial of Stp705 for Treatment of Cutaneous Basal Cell Carcinoma

Sirnaomics Ltd. Receives Safe to Proceed Letter for U.S. FDA Investigational New Drug Application for Systemic RNAi Therapeutic STP707 in Primary Sclerosing Cholangitis (PSC)

Sirnaomics Launches Phase I Clinical Trial of Rnai Therapeutic Stp707 Delivered Systemically for the Treatment of Solid Tumors

Non Executive Director recently bought HK$371k worth of stock

Non Executive Director recently bought HK$11m worth of stock

Less than half of directors are independent

Sirnaomics Ltd. has completed an IPO in the amount of HKD 496.886 million.

CEO

Görev süresi

Yönetim Kurulu Üyeleri

Ortalama Görev Süresi